<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9328">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05700396</url>
  </required_header>
  <id_info>
    <org_study_id>22-509</org_study_id>
    <nct_id>NCT05700396</nct_id>
  </id_info>
  <brief_title>Breast Cancer Survivor Educational Intervention</brief_title>
  <official_title>Increasing Receipt of Guideline Concordant Survivorship Care Among Black Breast Cancer Survivors Through Patient Education</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Cancer Society, Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to test a 6-week virtual education program among Black breast&#xD;
      cancer survivors. The virtual program includes sessions on physical activity, goal setting,&#xD;
      nutrition, sleep, stress, and social connections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This six-week feasibility study will evaluate a virtual support and education program among&#xD;
      up to 15 Black female breast cancer survivors. Participants will be asked to attend a 90&#xD;
      minute group session once a week for 6 weeks and complete surveys pre and post intervention&#xD;
      surveys to ascertain study endpoints. This study is supported by funding from Pfizer and&#xD;
      in-kind support from the American Cancer Society, Inc.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2023</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment Retention Rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the number of recruited participants who initiate intervention program.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time Required to Recruit to Target</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the amount of time to target accrual goal.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Eligible Participants</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the number of eligible participants required to recruit required sample size.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Intervention Completion</measure>
    <time_frame>6 weeks</time_frame>
    <description>Defined as the number of participants who attend at least 5 of 6 sessions.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Success Rate of Educational Intervention</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of participants &quot;very satisfied&quot; or &quot;completely satisfied&quot; with intervention. Defined successful if true of 80% of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Data collection feasibility</measure>
    <time_frame>6 weeks</time_frame>
    <description>Proportion of participants completing evaluation surveys each at baseline and week 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Self-Efficacy for symptom self-management</measure>
    <time_frame>6 weeks</time_frame>
    <description>Self-Efficacy for symptom self-management will be assessed using Symptom-Management Self-Efficacy Scale-Breast Cancer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intention to Receive post-treatment Surveillance Mammography</measure>
    <time_frame>6 weeks</time_frame>
    <description>Intention to Receive post-treatment Surveillance Mammography will be assessed using Follow-Up Care Use and Health Outcomes of Cancer Survivors (FOCUS) Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Activity Goal Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Physical Activity Goal Change will be assessed using Follow-Up Care Use and Health Outcomes of Cancer Survivors (FOCUS) Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dietary Behavior Goal Change</measure>
    <time_frame>6 weeks</time_frame>
    <description>Dietary Behavior Goal Change will be assessed using Follow-Up Care Use and Health Outcomes of Cancer Survivors (FOCUS) Survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unmet information Needs</measure>
    <time_frame>6 weeks</time_frame>
    <description>Unmet information Needs will be assessed using Follow-Up Care Use and Health Outcomes of Cancer Survivors (FOCUS) Survey</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Carcinoma</condition>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Breast Cancer Survivor Education Program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will complete study procedures as outlined:&#xD;
- 6 weekly sessions of a modified version of the PAVING the Path to Wellness education program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Breast Cancer Survivor Education Program</intervention_name>
    <description>Weekly sessions via Zoom platform with study staff.</description>
    <arm_group_label>Breast Cancer Survivor Education Program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
          -  Self-identified Black or African American race&#xD;
&#xD;
          -  Age 22-79&#xD;
&#xD;
          -  Diagnosis of Stage I, II, or III invasive breast cancer&#xD;
&#xD;
          -  Completed active treatment at least 6 months ago, but within the past five years&#xD;
&#xD;
          -  Speaks English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Undergoing active treatment (i.e., surgery, chemotherapy, radiation)&#xD;
&#xD;
          -  Undergoing evaluation for suspected recurrence&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erica Warner, MPH, ScD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amy Comander, MD</last_name>
    <role>Study Director</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Naomi Ko, MD</last_name>
    <role>Study Director</role>
    <affiliation>Boston Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Erica Warner, MPH, ScD</last_name>
    <phone>617-724-9516</phone>
    <email>ewarner@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Audra Hite</last_name>
    <email>mghbcss@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Warner, MPH, ScD</last_name>
      <phone>617-724-9516</phone>
      <email>ewarner@mgh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>March 27, 2023</last_update_submitted>
  <last_update_submitted_qc>March 27, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 28, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Erica T. Warner, ScD MPH</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Breast Carcinoma</keyword>
  <keyword>Breast Cancer Female</keyword>
  <keyword>Breast cancer survivor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>Contact the Partners Innovations team at http://www.partners.org/innovation</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

